Business Context and Reporting Period
This Form 8-K Current Report is filed by enGene Therapeutics Inc. (ENGN) for the reporting period of July 15, 2026. The filing addresses corporate governance changes, specifically the resignation of a director and the appointment of a new chairman.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on personnel changes and does not contain financial statements or performance data.
Material Changes
- Resignation: Dr. Richard Glickman resigned as a director and chairman of the Board of Directors, effective immediately on July 15, 2026.
- Reason for Departure: The resignation was not due to any disagreement with the Company regarding operations, policies, or practices.
- Succession: Current Board member Michael Heffernan was appointed as the new chairman of the Board.
Guidance, Outlook, and Risks
The filing does not contain updated financial guidance, operational outlook, or new risk factors. The Company issued a press release on July 16, 2026, to disclose these governance changes under Regulation FD. No unusual items or contingencies were reported in this document.
Investor Verification Checklist
- Verify the effective date of Dr. Glickman's resignation (July 15, 2026).
- Confirm the appointment of Michael Heffernan as the new Board Chairman.
- Review the attached press release (Exhibit 99.1) for additional context on the leadership transition.
- Note that no financial performance data is included in this specific filing.